CAMBRIDGE, Mass., June 9 /PRNewswire-FirstCall/ -- Biopure Corporation
(Nasdaq: BPUR) today announced that it has sent an open letter to the
editors of the Journal of the American Medical Association (JAMA). The
letter asks for a retraction of the meta-analysis and the accompanying
editorial that appeared on line on April 28, 2008 and in the later print
edition, as well as an apology to the hemoglobin-based oxygen carrier
(HBOC) field. The letter and Biopure's analysis have been posted at
http://www.biopure.com.
"Considering the publicity that's been generated by both the authors of
the analysis and JAMA itself, we've taken the unusual step of sending an
open letter addressing the fallacy of this study and the impact of its
publication by JAMA," said Zafiris G. Zafirelis, Biopure CEO.
Biopure Corporation
Biopure Corporation develops, manufactures and markets pharmaceuticals,
called oxygen therapeutics, that are intravenously administered to deliver
oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250
(bovine)], or HBOC-201, is approved for sale in South Africa for the
treatment of surgical patients who are acutely anemic. The company is
developing Hemopure for other indications and is supporting the U.S. Navy's
government-funded efforts to develop a potential out-of-hospital trauma
indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer
- 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for
marketing by both the U.S. Food and Drug Administration and the European
Commission, is indicated for the treatment of anemia in dogs. Biopure has
sold approximately 200,000 units of Oxyglobin since its launch.
Contact: Tiana Gorham
Biopure Corporation
(617) 234-6826
IR@biopure.com
SOURCE Biopure Corporation
 back to top
Related links:
http://www.biopure.com
http://www.prnewswire.com/comp/131224.html /
CONTACT:
Tiana Gorham of Biopure Corporation,
+1-617-234-6826, IR@biopure.com
|
